The E3 ligase HACE1 is a critical chromosome 6q21 tumor suppressor involved in multiple cancers

Nature Medicine

Volumn 13, Issue 9, 2007, Pages 1060-1069

  Zhang, Liyong ^a,b   Anglesio, Michael S ^c,e   O'Sullivan, Maureen ^c,e   Zhang, Fan ^c,e   Yang, Ge ^b   Sarao, Renu ^a,b   Nghiem, Mai P ^a,b   Cronin, Shane ^a   Hara, Hiromitsu ^a   Melnyk, Nataliya ^c,e   Li, Liheng ^c,e   Wada, Teiji ^a   Liu, Peter P ^b   Farrar, Jason ^d   Arceci, Robert J ^d   Sorensen, Poul H ^c,e   Penninger, Josef M ^a  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^b UNIVERSITY OF TORONTO   (Canada)

^c BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN HACE1; PROTEIN P53; SMALL INTERFERING RNA; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER; CANCER INCIDENCE; CELL CYCLE PROGRESSION; CELL STRESS; CHROMOSOME 6Q; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; ENZYME ACTIVITY; FEMALE; GENE ACTIVATION; GENE EXPRESSION; GROWTH; HACE1 GENE; HETEROZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; TUMOR SUPPRESSOR GENE;

ANIMALS; ANKYRIN REPEAT; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 6; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KIDNEY NEOPLASMS; MICE; MICE, MUTANT STRAINS; RNA, MESSENGER; UBIQUITIN-PROTEIN LIGASES; WILMS TUMOR;

MUS;

EID: 34948840375     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1621     Document Type: Article

References (45)

1. Thiagalingam, S. et al. Loss of heterozygosity as a predictor to map tumor suppressor genes in cancer: molecular basis of its occurrence. Curr. Opin. Oncol. 14, 65-72 (2002).
2. Hyytinen, E.R. et al. Defining the region(s) of deletion at 6q16-q22 in human prostate cancer. Genes Chromosom. Cancer 34, 306-312 (2002).
3. Inoue, M. et al. Chromosome 6 suffers frequent and multiple aberrations in thymoma. Am. J. Pathol. 161, 1507-1513 (2002).
4. Orphanos, V. et al. Allelic imbalance of chromosome 6q in ovarian tumors. Br. J. Cancer 71, 666-669 (1995).
5. Utada, Y. et al. Mapping of target regions of allelic loss in primary breast cancers to 1-cM intervals on genomic contigs at 6q21 and 6q25.3. Jpn. J. Cancer Res. 91, 293-300 (2000).
6. Zhang, Y. et al. A 3-cM commonly deleted region in 6q21 in leukemias and lymphomas delineated by fluorescence in situ hybridization. Genes Chromosom. Cancer 27, 52-58 (2000).
7. Morelli, C. et al. Cloning and characterization of the common fragile site FRA6F harboring a replicative senescence gene and frequently deleted in human tumors. Oncogene 21, 7266-7276 (2002).
8. Fernandez, C.V., Lestou, V.S., Wildish, J., Lee, C.L. & Sorensen, P.H. Detection of a novel t(6;15)(q21;q21) in a pediatric Wilms' tumor. Cancer Genet. Cytogenet. 129, 165-167 (2001).
9. Solis, V., Pritchard, J. & Cowell, J.K. Cytogenetic changes in Wilms' tumors. Cancer Genet. Cytogenet. 34, 223-234 (1988).
10. Hoban, P.R. et al. Physical localisation of the breakpoints of a constitutional translocation t(5;6)(q21;q21) in a child with bilateral Wilms' tumor. J. Med. Genet. 34, 343-345 (1997).
11. Bruce, C.K., Howard, P., Nowak, N.J. & Hoban, P.R. Molecular analysis of region t(5;6)(q21;q21) in Wilms tumor. Cancer Genet. Cytogenet. 141, 106-113 (2003).
12. Anglesio, M.S. et al. Differential expression of a novel ankyrin containing E3 ubiquitin-protein ligase, Hace1, in sporadic Wilms' tumor versus normal kidney. Hum. Mol. Genet. 13, 2061-2074 (2004).
13. Huibregtse, J.M., Scheffner, M., Beaudenon, S. & Howley, P.M. A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. Proc. Natl. Acad. Sci. USA 92, 2563-2567 (1995).
14. Jones, P.A. & Baylin, S.B. The epigenomics of cancer. Cell 128, 683-692 (2007).
15. Sharpless, N.E. et al. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 413, 86-91 (2001).
16. Sharpless, N.E. et al. p16INK4a and p53 deficiency cooperate in tumorigenesis. Cancer Res. 62, 2761-2765 (2002).
17. ARF, which confers selection in mouse lung tumori-genesis. Mol. Carcinog. 25, 92-98 (1999).
18. Jackson, R.J. et al. Loss of the cell cycle inhibitors p21(Cip1) and p27(Kip1) enhances tumorigenesis in knockout mouse models. Oncogene 21, 8486-8497 (2002).
19. Donehower, L.A. et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 356, 215-221 (1992).
20. Harvey, M. et al. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat. Genet. 5, 225-229 (1993).
21. Fogh, J., Fogh, J.M. & Orfeo, T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59, 221-226 (1977).
22. Lovvorn, H.N., III, Savani, R.C., Ruchelli, E., Cass, D.L. & Adzick, N.S. Serum hyaluronan and its association with unfavorable histology and aggressiveness of heterotransplanted Wilms' tumor. J. Pediatr. Surg. 35, 1070-1078 (2000).
23. Bagui, T.K., Mohapatra, S., Haura, E. & Pledger, W.J. P27Kip1 and p21Cip1 are not required for the formation of active D cyclin-cdk4 complexes. Mol. Cell. Biol. 23, 7285-7290 (2003).
24. Diehl, J.A., Cheng, M., Roussel, M.F. & Sherr, C.J. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12, 3499-3511 (1998).
25. Malumbres, M. & Barbacid, M. To cycle or not to cycle: a critical decision in cancer. Nat. Rev. Cancer 1, 222-231 (2001).
26. Jones, P.A. & Baylin, S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3, 415-428 (2002).
27. Diehl, J.A. Cycling to cancer with cyclin D1. Cancer Biol. Ther. 1, 226-231 (2002).
28. Kozar, K. et al. Mouse development and cell proliferation in the absence of D-cyclins. Cell 118, 477-491 (2004).
29. Bock, C. et al. BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. Bioinformatics 21, 4067-4068 (2005).
30. Tognon, C.E. et al. Regulation of RasGRP via a phorbol ester-responsive C1 domain. Mol. Cell. Biol. 18, 6995-7008 (1998).
31. Tognon, C. et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2, 367-376 (2002).
32. Thomas, N.A., Neville, P.J., Baxter, S.W. & Campbell, I.G. Genetic analysis of benign ovarian tumors. Int. J. Cancer 105, 499-505 (2003).
33. Gaidano, G. et al. Deletions involving two distinct regions of 6q in B-cell non-Hodgkin lymphoma. Blood 80, 1781-1787 (1992).
34. Takeuchi, S. et al. Allelotype analysis in relapsed childhood acute lymphoblastic leukemia. Oncogene 22, 6970-6976 (2003).
35. Li, B.C. et al. Allelic loss of chromosome 6q in gastric carcinoma. Diagn. Mol. Pathol. 12, 193-200 (2003).
36. Yoon, J. & Ko, Y.H. Deletion mapping of the long arm of chromosome 6 in peripheral T and NK cell lymphomas. Leuk. Lymphoma 44, 2077-2082 (2003).
37. Fujii, H., Zhou, W. & Gabrielson, E. Detection of frequent allelic loss of 6q23-q25.2 in microdissected human breast cancer tissues. Genes Chromosom. Cancer 16, 35-39 (1996).
38. Fujii, S., Takeshima, Y., Arihiro, K., Kaneko, M. & Inai, K. Microsatellite instability in breast cancers with special reference to patients' age and bilaterality. Hiroshima J. Med. Sci. 47, 89-97 (1998).
39. Fujii, H. et al. Mucinous cancers have fewer genomic alterations than more common classes of breast cancer. Breast Cancer Res. Treat. 76, 255-260 (2002).
40. Trink, B. et al. Absence of TSG101 transcript abnormalities in human cancers. Oncogene 16, 2815-2818 (1998).
41. Smeds, J. et al. Ductal carcinoma in situ of the breast with different histopathological grades and corresponding new breast tumor events: analysis of loss of heterozygosity. Acta Oncol. 44, 41-49 (2005).
42. Yatsuoka, T. et al. Association of poor prognosis with loss of 12q, 17p, and 18q, and concordant loss of 6q/17p and 12q/18q in human pancreatic ductal adenocarcinoma. Am. J. Gastroenterol. 95, 2080-2085 (2000).
43. Konishi, N. et al. Genetic mapping of allelic loss on chromosome 6q within heterogeneous prostate carcinoma. Cancer Sci. 94, 764-768 (2003).
44. Nakamura, M. et al. Novel tumor suppressor loci on 6q22-23 in primary central nervous system lymphomas. Cancer Res. 63, 737-741 (2003).
45. Barghorn, A. et al. Putative tumor suppressor loci at 6q22 and 6q23-q24 are involved in the malignant progression of sporadic endocrine pancreatic tumors. Am. J. Pathol. 158, 1903-1911 (2001).